Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany.
Department of Biomedicine, University of Bergen, Bergen, Norway.
PLoS One. 2019 May 8;14(5):e0216132. doi: 10.1371/journal.pone.0216132. eCollection 2019.
Golgi α-mannosidase II (GMII) is a glycoside hydrolase playing a crucial role in the N-glycosylation pathway. In various tumour cell lines, the distribution of N-linked sugars on the cell surface is modified and correlates with the progression of tumour metastasis. GMII therefore is a possible molecular target for anticancer agents. Here, we describe the identification of a non-competitive GMII inhibitor using computer-aided drug design methods including identification of a possible allosteric binding site, pharmacophore search and virtual screening.
高尔基 α-甘露糖苷酶 II(GMII)是糖苷水解酶,在 N-糖基化途径中发挥着关键作用。在各种肿瘤细胞系中,细胞表面 N-连接糖的分布发生改变,并与肿瘤转移的进展相关。因此,GMII 是抗癌药物的一个潜在的分子靶点。在这里,我们描述了使用计算机辅助药物设计方法鉴定非竞争性 GMII 抑制剂的过程,包括确定可能的别构结合位点、药效团搜索和虚拟筛选。